RecruitingNCT06657430
A Study on the Preference of Risperidone Dosage Forms
Sponsor
Shanghai Mental Health Center
Enrollment
1,000 participants
Start Date
Sep 19, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study aimed to understand patients' needs and preferences for antipsychotic dosage forms.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This survey-based study explores which form of risperidone — a psychiatric medication — patients or their caregivers prefer: tablets, liquid, or long-acting injections. It aims to understand patient preferences to improve medication adherence.
**You may be eligible if...**
- You or your child has been diagnosed with schizophrenia, bipolar disorder, autism spectrum disorder, or intellectual disability
- You are a patient or primary caregiver willing to voluntarily participate
- You can read and understand Chinese
**You may NOT be eligible if...**
- You have difficulty reading or understanding Chinese
- You decline to participate
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06657430
Related Trials
Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study
NCT073044401 location
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT0710511122 locations
Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate
NCT063407891 location
Investigating Autimia, a Digital Intervention for Patients With Autism Spectrum Disorder
NCT076386571 location
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
NCT070612888 locations